SCHEMBL21364059

SCHEMBL21364059

COCCOc1ncc2[nH]c(=O)n(Cc3ccc(C#N)cc3F)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.49
JAK3 P52333 5/20 0.49
USP1 O94782 3/20 0.42
TLR7 Q9NYK1 4/20 0.41
NUDT1 P36639 2/20 0.41
ALDH1A1 P00352 5/20 0.41
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 4/20 0.41
CYP2C9 P11712 4/20 0.41
CYP2C19 P33261 3/20 0.41
HSD17B10 Q99714 2/20 0.41
CASP1 P29466 1/20 0.41
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
USP2 O75604 2/20 0.38
HIF1A Q16665 1/20 0.38
MAPK1 P28482 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90B1 P14625 1/20 0.37
TRAP1 Q12931 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157446 0.85 USP1 (0.57) JAK2JAK3USP1TLR7NUDT1
SCHEMBL20157659 0.84 USP1 (0.43) JAK2JAK3USP1TLR7NUDT1
SCHEMBL20157144 0.84 TLR7 (0.49) JAK2JAK3USP1TLR7NUDT1
SCHEMBL20157621 0.82 USP1 (0.45) JAK2JAK3USP1TLR7NUDT1
SCHEMBL20157657 0.81 TLR7 (0.46) USP1TLR7NUDT1
SCHEMBL20157619 0.80 TLR7 (0.46) USP1TLR7NUDT1
SCHEMBL20157458 0.79 USP1 (0.47) USP1TLR7NUDT1ALDH1A1CYP1A2
SCHEMBL20157622 0.75 TLR7 (0.46) JAK2JAK3USP1TLR7NUDT1
SCHEMBL20157159 0.75 USP1 (0.52) JAK2JAK3USP1ALDH1A1KDM4E
SCHEMBL20157643 0.74 GRIN1 (0.46) JAK2JAK3USP1TLR7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084818-B2 Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use HEPO PHARMACEUTICAL CO., LTD. (CN) 2021-08-10 US disclosed
US-20200062758-A1 Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use HEPO PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3539963-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE Livo (Shanghai) Pharmaceutical Co., Ltd (CN) 2019-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084818-B2 Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use TLR7, TLR9, TLR4 JAK2 140/4885JAK3 577/4885USP1 3017/4885
US-20200062758-A1 Nitrogen-Containing Heterocyclic Compound, Preparation Method, Intermediate, Pharmaceutical Composition and use TLR7, TLR9, NOD1 JAK2 300/4885JAK3 868/4885USP1 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.